Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.
The role of histone deacetylase inhibitors in metastatic breast cancer / B. Zucchetti, A.K. Shimada, A. Katz, G. Curigliano. - In: THE BREAST. - ISSN 0960-9776. - 43:(2019 Feb), pp. 130-134. [10.1016/j.breast.2018.12.001]
The role of histone deacetylase inhibitors in metastatic breast cancer
G. Curigliano
Ultimo
Writing – Review & Editing
2019
Abstract
Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.File | Dimensione | Formato | |
---|---|---|---|
HDAC Curigliano.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
520.11 kB
Formato
Adobe PDF
|
520.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.